Sometimes size doesn't matter: reevaluating RECIST and tumor response rate endpoints.
about
Phase II clinical trial of sorafenib in metastatic medullary thyroid cancerTest-retest reproducibility analysis of lung CT image featuresCurrent and emerging quantitative magnetic resonance imaging methods for assessing and predicting the response of breast cancer to neoadjuvant therapy.Improving CT prediction of treatment response in patients with metastatic colorectal carcinoma using statistical learning theoryA phase II trial of sorafenib in relapsed and unresectable high-grade osteosarcoma after failure of standard multimodal therapy: an Italian Sarcoma Group study.Tumor sensitive matching flow: A variational method to detecting and segmenting perihepatic and perisplenic ovarian cancer metastases on contrast-enhanced abdominal CT.New imaging approaches for understanding lung cancer response to treatment.Objective assessment of tumour response to therapy based on tumour growth kinetics.Patterns of disease progression in metastatic renal cell carcinoma patients treated with antivascular agents and interferon: impact of therapy on recurrence patterns and outcome measures.γ-H2AX and other histone post-translational modifications in the clinic.Role of vaccine therapy in cancer: biology and practiceAnti-idiotype antibodies in cancer treatment: the pharmaceutical industry perspective.Phase 2 trial of concurrent bevacizumab and transhepatic arterial chemoembolization in patients with unresectable hepatocellular carcinoma.A preclinical model for predicting drug response in soft-tissue sarcoma with targeted AAVP molecular imaging.The differential effects of metronomic gemcitabine and antiangiogenic treatment in patient-derived xenografts of pancreatic cancer: treatment effects on metabolism, vascular function, cell proliferation, and tumor growth.Modeling efficacy of bevacizumab treatment for metastatic colon cancer.Cancer vaccines: moving beyond current paradigms.Paradigm shifts in cancer vaccine therapy.Phase II trial of sorafenib in metastatic thyroid cancerRECIST 1.1 and serum thyroglobulin measurements in the evaluation of responses to sorafenib in patients with radioactive iodine-refractory differentiated thyroid carcinoma.Liver Tumor Segmentation from MR Images Using 3D Fast Marching Algorithm and Single Hidden Layer Feedforward Neural NetworkA mechanically coupled reaction-diffusion model for predicting the response of breast tumors to neoadjuvant chemotherapy.PET imaging for Treatment Response in CancerPotential of compressed sensing in quantitative MR imaging of cancer.Reproducibility and Prognosis of Quantitative Features Extracted from CT ImagesAutomated tracking of quantitative assessments of tumor burden in clinical trials.Opportunities and pitfalls of cancer imaging in clinical trials.FDG-PET/CT response evaluation during EGFR-TKI treatment in patients with NSCLC.Three-dimensional Image-based Mechanical Modeling for Predicting the Response of Breast Cancer to Neoadjuvant Therapy.Dynamic contrast-enhanced MRI parameters as biomarkers for the effect of vatalanib in patients with non-small-cell lung cancer.Fever-range whole-body thermal therapy combined with cisplatin, gemcitabine, and daily interferon-alpha: a description of a phase I-II protocol.Drugs for solid cancer: the productivity crisis prompts a rethink.Predictive and prognostic value of early response assessment using 18FDG-PET in advanced non-small cell lung cancer patients treated with erlotinib.Automatic lung tumor segmentation with leaks removal in follow-up CT studies.Automatic detection of new tumors and tumor burden evaluation in longitudinal liver CT scan studies.Dynamic contrast-enhanced magnetic resonance imaging and diffusion-weighted magnetic resonance imaging for predicting the response of locally advanced breast cancer to neoadjuvant therapy: a meta-analysis.Trends in endpoint selection in clinical trials of advanced breast cancer.Liver tumors segmentation from CTA images using voxels classification and affinity constraint propagation.Compliance with PET acquisition protocols for therapeutic monitoring of erlotinib therapy in an international trial for patients with non-small cell lung cancer.Visceral and subcutaneous fat as new independent predictive factors of survival in locally advanced gastric carcinoma patients treated with neo-adjuvant chemotherapy.
P2860
Q27851560-F5A96D83-FEEC-44E6-AB09-D8068D5F3AB1Q28649954-AAF7EB78-3E0C-48C1-B67E-0716321782B9Q30460977-B0B171EC-08DC-4AA4-AB3B-9AB5F7B179C4Q33766595-91B590E4-ED1C-43C9-8FE7-233DB7A3FEABQ34628840-F1CF969A-D422-4923-924C-93B126062354Q35019152-15718333-9573-4ECE-AE9A-A7DFB704A594Q35200105-A43AD2B3-BD65-40CD-ADDC-C1D785265B7DQ35287641-7AC7256C-8F01-44A0-8DB7-29FB321EB912Q35684252-FA5B454B-098F-45DC-99B1-717761DF5248Q36019818-34A52908-7895-48B5-9FEB-1B2AE337B032Q36256420-E46CAA0F-F182-4D50-BD39-BA58FED740DAQ36352693-7208E0DE-22D8-4E11-BA49-A7ADAA0F086BQ36625954-EDDA833C-C99A-4CEA-B1A4-71FC489F4E40Q36670260-1A5854C5-0D8E-47A9-80DF-8895C653896CQ36761584-51B49B02-D90D-4506-8AC0-F5C6E507EA33Q36845505-17EE8A28-B198-4B3A-B7D5-D4BA8FBCC46CQ36868126-F88D215C-4D2C-4EBD-8765-386E6F1ACAE6Q37122893-49AC0517-E4C6-488F-942A-5150ECA6208FQ37158278-5CE51ADF-4D67-4CFD-84D9-21B5857C6B82Q37211774-8782CC0B-8998-4EC0-AFAD-0039CFE18CADQ37212335-241A393D-CC25-4172-A2F9-596942F2107DQ37218930-035DA323-6A49-4D87-8D2B-5D8C050406C2Q37465205-38741E0B-E885-4CB7-BBB3-3AAF10B4B944Q37487052-B7B655B6-6F95-4F9D-90F2-F25E0779390DQ37721549-6F1CAE52-6214-4A8F-BA54-9D619CC1F037Q37721552-D7EA5FE4-F105-49BB-BCAE-D60DBD4605B8Q37869334-E5BB073B-B2C7-4DFA-AD42-8F7BF41461A8Q38234978-8D2F656C-23CD-4B38-A56B-59932C131F4EQ39044851-A7DB1757-7B92-40C9-BBB6-EDC8CE568D6FQ39198025-494C9053-F21D-4888-A0E9-F6B71C8F66E4Q40414815-FD8A53B0-9021-4026-BA26-1BD00675A31DQ41313977-1EE8B20B-522E-4717-842D-31DF845E1658Q43605684-44089A5A-0D78-4777-BC3E-A273FA35A266Q46207858-F15E49B2-80A4-4ED8-831D-F0AD96555B69Q46772575-95D44202-D91E-4A50-B681-5FF4D408BB72Q47287018-1F7F65CC-89FE-4BA4-9F00-1E60D4F19BCDQ50160426-D174DCF6-7645-4144-A0ED-8EB7B634AAB3Q51686495-1B63F170-401B-47A0-87F4-CFF7D222AF34Q53161184-D2D0D5EC-6035-4724-8F73-DA4F8AAB2062Q53225944-4A3B00ED-9632-4565-8232-16BD8A08D95B
P2860
Sometimes size doesn't matter: reevaluating RECIST and tumor response rate endpoints.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年学术文章
@wuu
2006年学术文章
@zh
2006年学术文章
@zh-cn
2006年学术文章
@zh-hans
2006年学术文章
@zh-my
2006年学术文章
@zh-sg
2006年學術文章
@yue
2006年學術文章
@zh-hant
name
Sometimes size doesn't matter: reevaluating RECIST and tumor response rate endpoints.
@en
Sometimes size doesn't matter: reevaluating RECIST and tumor response rate endpoints.
@nl
type
label
Sometimes size doesn't matter: reevaluating RECIST and tumor response rate endpoints.
@en
Sometimes size doesn't matter: reevaluating RECIST and tumor response rate endpoints.
@nl
prefLabel
Sometimes size doesn't matter: reevaluating RECIST and tumor response rate endpoints.
@en
Sometimes size doesn't matter: reevaluating RECIST and tumor response rate endpoints.
@nl
P356
P1476
Sometimes size doesn't matter: reevaluating RECIST and tumor response rate endpoints.
@en
P2093
Rabiya S Tuma
P304
P356
10.1093/JNCI/DJJ403
P407
P577
2006-09-01T00:00:00Z